Novartis stock holds above $150 after orphan drug update
Published on 08/19/2026 at 17:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis AG stock (CH0012005267) closed at $151.97 on August 17, 2026, and the latest US quote in the session showed $150.98 at 12:02 p.m. EDT on August 19, 2026. The move sits against a market value of $287.90 billion and a recent regulatory update that gave investors a fresh reason to stay engaged.
Recent coverage says Novartis announced orphan-drug designation for iptacopan in atypical hemolytic uremic syndrome on August 18, 2026. That same coverage places the shares at $154.55 on August 18, 2026, which is 18.5 percent above a $130.41 fair-value benchmark in the article.
Pipeline catalyst
For Novartis, the key point is not just the designation itself but what it signals about the rare-disease franchise around iptacopan. The drug is still investigational, yet the update extends a pipeline that is already tied to specialty medicine revenue potential if later-stage work and approvals progress.
The valuation picture adds another layer. The article cites an average analyst target of $141.20, a low target of $112.00 and a high target of $180.00, putting the latest US quote above the average but below the top of the range.
Trading stays firm
Novartis AG also traded at CHF 125.96 in a live estimate on August 19, 2026, with a 5-day change of 1.61 percent and a year-to-date change of 15.15 percent on that page. The same source listed a mean analyst consensus of HOLD from 22 analysts and an average target price of $154.17, which leaves the US share price close to that level.
That mix matters for investors because it connects a near-term regulatory catalyst with pricing that already reflects much of the optimism. The shares have moved within a narrow band above $150 in US trading while still showing double-digit year-to-date gains in Swiss-market terms.
Leqvio and Entresto
One representative Novartis product is Leqvio, an inclisiran therapy that the company will feature in cardiovascular data at ESC Congress 2026. Another visible part of the portfolio is Entresto, which remains one of the group's most recognizable medicines and continues to anchor the cardiovascular franchise.
Those names matter because Novartis is using established brands and newer pipeline assets together rather than leaning on a single catalyst. The August 19, 2026 congress program underscores that mix with 10 abstracts across the cardiovascular portfolio.
Novartis stock at a glance
Novartis stock remains a large-cap health care name with a clear mix of live market support, pipeline news and valuation discipline. As of August 17, 2026, the shares stood at $151.97 in the US and the market cap was $287.90 billion.
ISIN: CH0012005267
Ticker: NVS
Exchange: New York Stock Exchange (ADR)
Price (as of August 17, 2026, 4:00 p.m. ET): $151.97 USD
Market cap: $287.90 billion (as of August 17, 2026)
Sector / Industry: Health care / Pharmaceuticals
Index membership: S&P 500
